Michaela Lessler, MD
Pulmonary Disease · Scottsdale, AZNPI 1710964275
Payments from drug & device makers
Across 142 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$529
- AstraZeneca$273
- Boehringer Ingelheim$231
- Sanofi$194
- Grifols USA, LLC$182
- Actelion Pharmaceuticals US, Inc.$163
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,933100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $529 |
| AstraZeneca | 16 | $273 |
| Boehringer Ingelheim | 11 | $231 |
| Sanofi | 8 | $194 |
| Grifols USA, LLC | 8 | $182 |
| Actelion Pharmaceuticals US, Inc. | 6 | $163 |
| United Therapeutics Corporation | 7 | $143 |
| Mylan Specialty L.p. | 6 | $129 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Insmed, Inc. | 7 | $119 |
| Covis Pharma GmbH | 4 | $115 |
| Amgen | 5 | $89 |
| Electromed, Inc. | 9 | $83 |
| Merck | 4 | $64 |
| Astellas Pharma US Inc | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Viatris Specialty LLC | 2 | $45 |
| Viiv Healthcare Company | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $37 |
| UCB, Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| CMP Pharma, Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Gilead | 1 | $20 |
| Circassia Inc. | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,933 in reported general payments places this provider in the 50th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $261,850 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 189 | $207,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $41,614 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $33,825 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $21,959 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $9,019 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,116 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,529 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,887 |
| Roflumilast | 61 | $5,996 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 150 | $5,333 |
| Fluconazole | 38 | $2,903 |
| Montelukast Sodium | 296 | $2,674 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $1,995 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $231 | $269,37931 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $529 | $248,392278 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $273 | $63,57292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Scottsdale
- Omar MohamedalyScottsdale$223K
- Karen SwansonScottsdale$173K
- Umesh GoswamiScottsdale$39K
- Suchitra PilliScottsdale$38K
- Yasemin TashmanScottsdale$21K
- Laszlo VaszarScottsdale$18K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.